Status:

COMPLETED

Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)

Lead Sponsor:

MCM Vaccines B.V.

Collaborating Sponsors:

Sanofi Pasteur, a Sanofi Company

Merck Sharp & Dohme LLC

Conditions:

Neisseria Meningitidis

Bacterial Infections

Eligibility:

All Genders

46-76 years

Phase:

PHASE3

Brief Summary

To evaluate the immune response and the safety of a primary series schedule that includes V419 (PR5I) at 2 and 6 months of age and Pediacel at 4 months of age Primary objectives * To demonstrate tha...

Eligibility Criteria

Inclusion

  • Healthy infant 46 to 74 days (both inclusive)
  • Documented receipt of only one dose of monovalent hepatitis B vaccine within the 3 days after birth
  • Parent(s)/legal representative able to comply with the study procedures

Exclusion

  • Participation in any study with an investigational compound or device since birth
  • History of congenital or acquired immunodeficiency
  • Chronic illness that could interfere with study conduct or completion
  • Hypersensitivity to any of the study vaccines components or history of a life-threatening reaction to a vaccine containing the same substances as the study vaccines
  • Contraindication to Pediacel®, NeisVac-C®, Prevenar 13®, and RotaTeq®
  • History or maternal history of HBsAg seropositivity
  • Coagulation disorder that contraindicate intramuscular injection
  • History of vaccination with a Haemophilus influenzae type b conjugate, diphtheria, tetanus, pertussis (acelullar or whole-cell), poliovirus, meningococcal serogroup C conjugate, pneumococcal conjugate containing vaccine(s)
  • History of hepatitis B, Haemophilus influenzae type b, diphtheria, tetanus, pertussis, poliomyelitis, or serogroup C meningococcal infection
  • Receipt of immune globulin, blood or blood-derived products since birth
  • Receipt of systemic corticosteroids for more than 14 consecutive days within one month of the study start
  • Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study

Key Trial Info

Start Date :

May 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 19 2014

Estimated Enrollment :

385 Patients enrolled

Trial Details

Trial ID

NCT01839188

Start Date

May 1 2013

End Date

March 19 2014

Last Update

February 25 2019

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.